{
  "documentMetadata": {
    "title": "Bursitis, Septic",
    "lastUpdated": "2024-04-12",
    "sourceFile": "Bursitis, Septic.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Swelling, tenderness, and erythema (over superficial bursae) of a bursal sac.",
        "Bursal fluid aspirate with 1000 to 20,000 polys/mm³.",
        "Positive culture."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus aureus (> 80%)",
        "Streptococci",
        "Rarely mycobacteria, fungi, other organisms"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "If MSSA:"
        },
        {
          "type": "list",
          "items": [
            "(Nafcillin or Oxacillin) 2 gm IV q4h or Cefazolin 2 gm IV q8h"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "If MRSA:"
        },
        {
          "type": "list",
          "items": [
            "Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) or Linezolid 600 mg po bid"
          ]
        }
      ]
    },
    {
      "type": "list",
      "items": [
        "Incision and drainage or daily aspiration until fluid stops accumulating"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "If MSSA: Dicloxacillin 500 mg po qid as oral step-down",
        "If MRSA: Daptomycin 6 mg/kg IV q24h or Linezolid 600 mg po bid"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy. Typically treat for 2 weeks, combined IV and oral, although duration of therapy seems not to be a risk factor for recurrence (Arch Orthop Trauma Surg. 2022;142:2445 and J Antimicrob Chemother 65:1008, 2010)",
        "Non-immunocompromised patients undergoing bursectomy may be cured with as little as a week of therapy."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Surgical excision of bursa reserved for more refractory cases.",
        "Review article: StatPearls Publishing; 2022 Jul 8.",
        "French guidelines: Joint Bone Spine. 2024; 91:105664."
      ]
    }
  ]
}